丙种球蛋白治疗重症手足口病疗效观察
Curative effects of immunoglobulin in the treatment of the sever Hand-foot-mouth disease
-
摘要: 目的:探讨丙种球蛋白治疗重症手足口病的疗效。方法:选择重症手足口病患儿42例,随机分为常规治疗组20例;丙种球蛋白治疗组22例,其中又分为单纯丙种球蛋白治疗(单纯治疗组)14例和甲泼尼龙与丙种球蛋白联合治疗(联合治疗组)8例。比较3组临床疗效。结果:与常规治疗组比较,联合治疗组和单纯治疗组体温恢复、皮疹消退和神经系统症状改善时间均明显缩短(P<0.01)。常规治疗组中7例无效或进展为危重症,联合治疗组中无进展或无效病例,单纯治疗组有1例进展为危重病例,3组无效或进展病例数差异有统计学意义(P<0.05)。结论:丙种球蛋白治疗重症手足口病能够缩短病程,改善预后。Abstract: Objective:To explore the curative effects of intravenous immunoglobulin(IVGV) in the treatment of the sever hand-foot-mouth disease(HFMD).Methods:Forty-two clildren with sever HFMD were divided into the conventional therapy group(20 cases) and immunoglobulin therapy group(22 cases).The immunoglobulin therapy group included 14 cases treated with single immunoglobulin(single therapy group) and 8 cases treated with immunoglobulin combined with methylprednisolone(combination therapy group).The curative effects between three groups were compared.Results:Compared with the conventional therapy group, the times of body temperature recovery, deflorescence and nervous system symptom improvement in the combination and single therapy groups were significantly shorter(P<0.01).The invalid or progress for the critical illness in 7 cases in the conventional therapy group, no invalid or progress case in the combination therapy group, and progress for the critical illness in 1 case in single therapy group were found.Compared with the conventional therapy group, the failed or progress case in single therapy group was less(P<0.05).Conclusions:The IVGV treatment can shorten the course and improve the prognosis of children with sever HFMD.
-
Key words:
- hand-foot-mouth disease /
- intravenous immunoglobulin /
- methylprednisolone
-
[1] 张克昌, 曹明杰, 李维春, 等.手足口病患儿体内淋巴细胞亚群和细胞因子水平变化及意义[J].山东医药, 2013, 53(7):19-22. [2] 金雅, 黎淑芬, 莫丽英.手足口病患儿激素治疗前后免疫球蛋白水平的变化分析[J].临床合理用药杂志, 2012, 5(22):123-124. [3] Lin TY, Chang LY, Huang YC, et al.Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections:implications for early recognition and therapy[J].Acta Paediatrica, 2002, 91(6):632-635. [4] 李素华, 陈雪夏, 林海龙, 等.丙种球蛋白对重症EV-71感染手足口病患儿细胞因子调节作用的研究[J].医学研究杂志, 2013, 42(6):111-115. [5] Wang SM, Lei HY, Huang MC, et al.Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis[J].J Clin Virol, 2006, 37(1):47-52. [6] 程红球, 黄彩华, 刘卫东, 等.丙种球蛋白对手足口病患者血循环中炎症细胞因子水平的影响[J].中国病理生理杂志, 2013, 29(3):546-548. [7] 逯广龙, 任雪云, 马本宽.不同剂量丙种球蛋白治疗重症手足口病的疗效观察[J].中国小儿急救医学, 2010, 17(3):274-275. [8] 于永锋, 初灵芝.不同剂量静脉注射人血免疫球蛋白治疗重症手足口病合并脑炎疗效分析[J].中华妇幼临床医学杂志:电子版, 2013, 9(2):184-186. [9] 江明, 王兴川.早期、足量甲基强的松龙联合丙种球蛋白治疗重症手足口病的临床研究[J].中华实验和临床病毒学杂志, 2013, 27(5):363-365. [10] 樊婷婷, 潘家华.不同剂量糖皮质激素治疗小儿重症手足口病2期的疗效观察[J].安徽医药, 2012, 16(4):541-546. [11] 王喆, 刘亚敏, 马敏君, 等.糖皮质激素治疗重症手足口病的临床意义[J].山东医药, 2012, 52(41):62-63. [12] 付丹, 李成荣, 何颜霞, 等.肠道病毒 71 型感染患儿免疫功能探讨[J].中华儿科杂志, 2009, 47(11):829-834. [13] Osuchowski MF, Welch K, Siddiqui J, et al.Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality[J].The Journal of Immunology, 2006, 177(3):1967-1974. [14] Lin YW, Chang KC, Kao CM, et al.Lymphocyte and antibody responses reduce entervirus 71 lethality in mice by decreasing tissue loads[J].J Virol, 2009, 83(13):6477-6483. [15] 武洁, 成怡冰, 李志方, 等.肠道病毒71型重症和危重症手足口病患儿肾上腺皮质功能状态评价[J].中华儿科杂志, 2012, 50(4):249-254. [16] 朱启镕, 黄立民, 杨思达, 等.手足口病临床分期及对策[J].中国循证儿科杂志, 2009, 4(3):241-248. -
点击查看大图
计量
- 文章访问数: 3957
- HTML全文浏览量: 563
- PDF下载量: 461
- 被引次数: 0
下载:
